Mucopolysaccharidosis II
Drug research and approvals for mucopolysaccharidosis II: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 10 studies of mucopolysaccharidosis II are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 10
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 1
- A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)NCT07640984 · Phase 1 / Phase 2 · JCR Pharmaceuticals Co., Ltd. · starts Sep 9, 2026
- MPS (RaDiCo Cohort) (RaDiCo-MPS)NCT06036693 · Not reported · Institut National de la Santé Et de la Recherche Médicale, France · starts Dec 20, 2017
- Registry of Patients Diagnosed With Lysosomal Storage DiseasesNCT05619900 · Not reported · University of California, San Francisco · starts May 31, 2022
- A Natural History Study in Children With a Type II Collagen Disorder With Short StatureNCT05408715 · Not reported · Innoskel · starts Jun 29, 2022
- PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)NCT04532047 · Phase 1 · University of California, San Francisco · starts Jul 1, 2021
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICNCT04528355 · Not reported · Paul Szabolcs · starts Aug 20, 2020
- Longitudinal Study of Neurodegenerative DisordersNCT03333200 · Not reported · University of Pittsburgh · starts Jan 11, 2012
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHNCT02716246 · Phase 2 / Phase 3 · Ultragenyx Pharmaceutical Inc · starts Apr 25, 2016
- UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like CellsNCT02254863 · Phase 1 · Joanne Kurtzberg, MD · starts Sep 1, 2014
Approved 1
- IdursulfaseHeparan sulfate hydrolytic enzyme
Phase 3 2
- Pabinafusp alfaDermatan sulfate hydrolytic enzyme
- Idursulfase betaHeparan sulfate hydrolytic enzyme
Phase 2 4
- Tividenofusp alfa
- AnakinraInterleukin-1 receptor antagonist
- SomatropinGrowth hormone receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
Phase 1 or earlier 2
- AdalimumabTNF-alpha inhibitor
- Clemidsogene lanparvovec
How its trials ended
70 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 15 whose ending is known, 47% met their primary endpoint, 0% missed it and 53% stopped early.
- Completed, result not reported2840%
- Ongoing2536%
- Met its primary endpoint710%
- Stopped: other or unclear34%
- Stopped: lack of efficacy23%
- Stopped: enrollment or feasibility23%
- Status unknown23%
- Stopped: sponsor or business decision11%
| Jul 24, 2006 | ElapraseIndicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Sep 1, 2016 | Recombinant adeno-associated virus vector serotype 9…Treatment of mucopolysaccharidosis II, also called Hunter syndrome A. | University of North Carolina at Chapel Hill | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jan 8, 2007 | ElapraseIdursulfase | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA